
Alterity Therapeutics (NASDAQ:ATHE) doses first subject in its Phase 2 clinical trial of lead candidate ATH434 in Multiple System Atrophy (MSA), a rare and highly debilitating Parkinsonian disorder.
The Phase 2 clinical trial is designed to investigate ATH434 in patients with early-stage Multiple System Atrophy (MSA).